Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402089 | 1.00 | ATP4A (1.00) | ATP4AATP4B | |
| Hydrochloric Acid SCHEMBL9652165 | 0.99 | ATP4A (0.98) | ATP4AATP4B | |
| SCHEMBL9653867 | 0.94 | ATP4A (0.89) | ATP4AATP4B | |
| SCHEMBL9652118 | 0.93 | ATP4A (0.86) | ATP4AATP4B | |
| SCHEMBL9318845 | 0.92 | ATP4A (0.85) | ATP4AATP4B | |
| SCHEMBL9650838 | 0.92 | ATP4A (0.85) | ATP4AATP4B | |
| SCHEMBL9318536 | 0.91 | ATP4A (0.84) | ATP4AATP4B | |
| SCHEMBL9319325 | 0.90 | ATP4A (0.82) | ATP4AATP4B | |
| SCHEMBL9269573 | 0.90 | ATP4A (0.82) | ATP4AATP4B | |
| SCHEMBL10498606 | 0.90 | ATP4A (0.81) | ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841904-B1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | ALTANA PHARMA AG (DE) | 2003-02-05 | — | — | EP | claimed |
| US-6132768-A | FOR TREATING DISORDERS CAUSED BY HELICOBACTER | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-17 | — | — | US | claimed |
| EP-0841904-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-05-20 | — | — | EP | claimed |
| WO-1997002021-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-01-23 | — | — | WO | claimed |
| EP-0259174-B1 | DERIVATIVES OF 4-AMINOQUINOLINE AND THEIR USE AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-03-18 | — | — | EP | claimed |
| US-4806549-A | INHIBITOR OF GASTRIC ACID SECRETION | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-21 | — | — | US | claimed |
| US-4806550-A | 4-Amino-3-carbonyl substituted quinolines as inhibitors of gastric acid secretion | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-21 | — | — | US | claimed |
| EP-0259174-A1 | Derivatives of 4-aminoquinoline and their use as medicaments | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-03-09 | — | — | EP | claimed |
| US-12616752-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12611413-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260077048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | AXSOME THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069603-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | AXSOME THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12551488-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12551489-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-4806549-A | INHIBITOR OF GASTRIC ACID SECRETION | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4806549-A | INHIBITOR OF GASTRIC ACID SECRETION | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4806550-A | 4-Amino-3-carbonyl substituted quinolines as inhibitors of gastric acid secretion | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4806550-A | 4-Amino-3-carbonyl substituted quinolines as inhibitors of gastric acid secretion | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-02-21 | — | — | US | disclosed |
| WO-1988001621-A1 | 4-AMINOQUINOLINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-03-10 | — | — | WO | disclosed |
| EP-0259174-A1 | Derivatives of 4-aminoquinoline and their use as medicaments | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551488-B2 | Pharmaceutical compositions comprising meloxicam | SLC10A2, SLC10A1, CALCA | ATP4A 567/4885ATP4B 1246/4885 |
| US-12616752-B2 | Pharmaceutical compositions comprising meloxicam | SLC10A2, SLC10A1, CALCA | ATP4A 611/4885ATP4B 941/4885 |
| US-20260077048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | SLC10A2, SLC10A1, CYP2C9 | ATP4A 508/4885ATP4B 752/4885 |
| US-20260069603-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | SLC10A2, MC4R, CA4 | ATP4A 248/4885ATP4B 480/4885 |
| US-12551489-B2 | Pharmaceutical compositions comprising meloxicam | SLC10A2, SLC10A1, CYP2C9 | ATP4A 426/4885ATP4B 796/4885 |
| US-12611413-B2 | Pharmaceutical compositions comprising meloxicam | SLC10A2, SLC10A1, MC3R | ATP4A 772/4885ATP4B 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.